ArticleJournal of materials science. Materials in medicine2026
Synergistic effects of erythropoietin and selenium enhance bone regeneration in ovariectomized rats.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporotic bone defects present formidable clinical challenges due to the limited capacity for natural bone repair. Erythropoietin (EPO) and Selenium (Se) have both demonstrated significant efficacy in enhancing bone regeneration; however, it remains unclear whether the combination of EPO and Se can further augment bone repair in the context of estrogen deficiency-induced osteoporosis. We undertook a study aimed at exploring the potential effects of localized implantation of materials incorporating EPO and/or Se on bone regeneration in rats subjected to osteoporosis via bilateral ovariectomy. Our observations revealed that local administration of EPO and Se over a period of 12 weeks effectively accelerated the healing process of osteoporotic bone defects, as evidenced by Micro-CT imaging and hematoxylin-eosin (HE) pathological staining. In addition, our findings from immunofluorescence assays, immunohistochemical analyses, and PCR testing indicate that local treatment with Se/EPO led to heightened expression levels of skeletal osteocalcin (OC), nuclear factor erythroid 2-related factor 2 (NRF2), and vascular endothelial growth factor (VEGF), alongside reduced expression levels of tartrate-resistant acid phosphatase (TRAP) in osteoporotic rats. Furthermore, this topical treatment exhibited conspicuous alterations in the expression profiles of key genes including osteoprotegerin (OPG), Runt-related transcription factor 2 (RUNX2), receptor activator of nuclear factor kappa-B ligand (RANKL), and sclerostin (SOST). Our results substantiate that localized administration utilizing Se/EPO holds considerable promise as an effective strategy for expediting the healing process associated with bone defects in cases of postmenopausal osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.